Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The broadening of Innovus, Amazon online sale is good news. I hope there is some targeted advertising and that it's not just dependent on reviews, or nothing.
Is the Beyond Human platform obsoleted, due to being on Amazon?
I think JB diver is right, Innovus is past being a business that benefits from hype. The most important thing now is that the hype actually turns into profits, meaning show us the money (not to sound greedy.)
I hope Innovus can lower it's operating costs, to become profitable soon. It could cost even more to sell overseas, but there's no doubt, it's great to expand Amazon sales.
Re: biotech2; The reason for the new, 52 week high, is because you keep buying shares of OVIT...
and since it's thinly traded, without a high float of shares, the stock is easily effected upward, but just a small purchase volume...
It's, easily effected, downward, by either a small volume of sells, or stagnation as well.
I hope your rumors of a sale or reverse merger are correct, because many have lost their shirts on OVIT and would like to recoup some of their losses.
Re: Drugdoctor; I don't want to fight with you...
Due to the lowered price of Fluticare, it's not at 81% profit.
For every $1dollar of products sold, it costs INNV at least $1.25, so the more Innovus sells, the less money Innovus makes.
Mainly, for profitability, Innovus needs to lower costs, advertise better and be on store shelves, in addition to being on Amazon, etc.
Re: Pennymonster1; It's the original Fluticare ANDA, (Abbrievated, New, Drug, Application) for OTC sales world-wide, not just USA sales.
Since, 2015 Dr.Damaj has been saying FDA approval is imminent, but it never happened and he even issued 25million shares to Novalere prematurely because of the ANDA, because Novalere had the agreement with the original manufacturing facility, either Hi-Tech or Akorn, I remember which one.
As a result, Dr.D, had to work out a lower-profit, back up plan with Westward, for Fluticare OTC, USA only sales.
GSK got FDA OTC, world-wide sales approval for Flonase in a few months after filing.
Re: loadedstoat; Agreed and hopefully the note holder or insider toxic debt holder will agree to that. I kept reading on here that it was an insider.
RE: loadedstoat; Ya, I agree with you. POTN should settle for money, not shares.
Re: Drugdoctor; Well, due to you being an Innovus "newbie" you're probably overly optimistic. Most posters agree that the only things that will boost share price is the approval of the ANDA, record breaking quarters and profitability. Unfortunately, good reviews on Amazon don't equal an increased share price, unless that contributes to great Q's.
Re: Rugdoctor; Ok, it's trading at .11 now.
Re: Drugdoctor; It's trading at .109 now. I didn't care it out to the hundreths of a penny, so just stated .10.
In order to find the Innovus share price, look on this site, google INNV stock, or log into your trading account for a real-time quote price.
Re: retired early; But for now, it's @ .10....
James Comey would. (I don't drink alcohol at all, quit years ago.)
ShawnP123 and JTaylor68, I'd like to have you both look each other in the eyes and with a firm handshake, say to each other...
"Look buddy, you're not completely wrong and I'm not completely right, we both want Innovus to succeed, so since we're both on the same team, let's bury the hatchet and hope for the best!"
Then, maybe have a cold beer and go your separate ways.
No need for a reverse shell merger, into another oncology biotech, due to cancer already being cured;
http://video.foxnews.com/v/5760261265001/?intcmp=ob_article_footer_text#sp=show-clips
Re: Drugdoctor; Neither, would rather wait, buy more and have a bigger profit.
Re: Drugdoctor; I can't sell, because I'm down 30-40% depending on the day, I'm so far underwater, I can't escape and it appears that I will be punished here for a long time to come.
Re: Pennymonster1; Is your "friend" and idiot? Was the $30 per share guess, after a major reverse split? Innovus will never get to $30 organically, not without successfully developing a research stage drug to treat a major indication that has few or no other treatments already available and Innovus is not even in that market, it's mostly natural OTC drug/supplements...
Re: Drugdoctor; Our lack of profitability and high expenses, even though there's an alleged profit margin of 80% is embarrassing and depressing...
Re: Drugdoctor;
I can see the potential for a good Q2, in part due to Fluticare sales. I could even believe Innovus might hit 4.5m in Q2.
I agree that Fluticare sales in will decrease in Q3 as the peak allergy season dissipates.
I'm sure that Q4, Fluticare, sales will drop to basically nothing, since the allergy season will be over and mostly, only, the less prevalent, in-door allergies would need to be treated.
If Innovus was selling Fluticare world-wide, then allergy season sales would always occur.
At this point, I think Innovus would be lucky, just to sell all of their 1st batch of 220,000 Fluticare units, which would actually include having had doctors give away free samples, as well as selling it for lowered prices/profits.
Yes, there are new-ish Innovus products ramping up closer to their full potential, such as Urivarx and Prostagorx.
The new diabetic products will take a while to ramp up, especially without any "good" advertising.
I could see where Innovus would have 9m in Q1+Q2 revs.
I don't count on another 9-10m in Q3+Q4.
In my opinion, there are no cinches here, like 1m in revs for 2018. 1m in revs for 2018 is not much, based on 19-20m in revs for 2018. Last year, Dr.D stated profitability could occur at between 10-15m.
Slowing down newspaper advertising would result in lower sales. Internet, radio and TV adverting are more effective than newspapers.
80% profits are not occuring with Fluticare, due to lowered prices. In general, I think Innovus products are priced to high.
It won't be easy to have net profits in 2018.
It might be a good idea to accumulate more throughout 2018 and hope for profitability at the end of 2019.
Re: Drugdoctor; Ya, that's good news for sure. Being in between the prices and ratings of Kirkland and Flonase is good. I hope the lowered cost of Fluticare will be made up for in a higher volume of sales.
I hope Innovus does a Fluticare reorder very soon, this time, for more than 220,000 units.
I hope the original Fluticare ANDA is approved soon, obviously it would broaden our sale scope, to worldwide and make us more attractive as a buy out target.
Re: Drugdoctor; Sorry, duh, I quickly skimmed your post and didn't see the link. As of checking now, GoodSense All Day Allergy, Cetirizine HCL Tablets, 10 mg, 365 Count was listed as number 1. I know these ratings change on a daily basis, but Fluticare is in the same ballpark as Flonase ratings, give or take a few.
Re: Drugdoctor; I agree, Fluticare having a #38 rating on Amazon is good. I'm curious now, what is ranked #1, do you know? Can you look it up and let us know? (I'm not being sarcastic.)
Re: Batermere; I'm glad to hear that good news. I'm hanging in as well and will buy more as capital becomes available, if the share price remains low for a while.
Re: JTaylore 68; Thank you very much! If this information is true, it restored some of my faith.
"Dr. Damaj amended an agreement and got a locking period for the Novalere shares in return to stabilize the share price when approval comes. He or rather the BOD didn't give anything away for nothing. Countless agreements are amended each and every day.
Damaj's and the BOD's decision might have very well turned out to be a very smart move had the FDA given approval in the most probable timeframe.
So again, it's an unfounded accusation to say Damaj gave away millions of shares to Novalere Holdings for nothing in return."
Re: Grizzly; Ok, my understand was that the preterm birth pill would be pushed forward, before Tlando.
Re: IanFromSi; I don't want you to believe anything, I was mentioning potential negative possibilities. I actually recommended Nuplazid to a freind of mine who takes care of her mother and she cited the CNN article as a reason not to try Nuplazid.
I don't think this type of situation will happen wide-spread, but since I know of it happening once, I hope it does not become a trend.
If it makes you feel better to be ultra-positive, then be my guest. I just hope CNN doesn't do another fake hit-piece...
Re: Matthew12321; Thank you for the detailed post regarding the toxic debt and renegotiating it.
Re: IanFromSI; Wow, that was a scathing rebuke of me.
I was not saying that Doctors are uneducated or fools, it was just a fear/concern of mine, that due to the CNN article, Nuplazid might be prescribed less...
I think ACAD recently stated that it could be a bumpy ride for a while. (Not sure about that, read it from another poster.)
As you can see, the CNN article caused a 50% drop in the share price, so fake or inaccurate news, often has a negative effect...
You and I know Nuplazid is good, but I hope everyone else knows. Here's another example of what could go wrong as a result CNNs bashing...
Adult children who have power of attorney over their elderly parents care, if they saw the CNN article, they could try and steer a good doctor against giving Nuplazid to their parent.
If you want to be happy and positive about the current share price and CNNs article blasting Nuplazid, then you're the naive one and you should stick to picking up empty beer bottles on the roadside...
RE: DogOnWeedStreet; Thank you for the detailed explanation.
Hmmm...A green day? There appears to be some buyers at this low, low price! Could this be that start of a Booh-Yah? Could my luck be turning around for the best?
Re: grizzly; Thanks for the reply. Do you know when the pre term birth pill will be under review by the FDA, for a NDA?
Thanks for the positive posts Harry. I hope you are right.
Investing, sometimes reminds me of being either a glutton for punishment, or being a heroin addict, who keeps going back to the drug, or someone who's lost a lot during a messy divorce, or someone that has to keep paying unrealistically high child support payments. I am none of those, but it feels like it.
Especially, after CNN posted a fake news article about the ACAD drug, Nuplazid being deadly and then the share price was cut in half overnight.
Investing, sometimes reminds me of being either a glutton for punishment, or being a heroin addict, who keeps going back to the drug, or someone who's lost a lot during a messy divorce, or someone that has to keep paying unrealistically high child support payments. I am none of those, but it feels like it.
Especially, after CNN posted a fake news article about the ACAD drug, Nuplazid being deadly and then the share price was cut in half overnight.
What's the next catalyst for ACAD? When is the FDA going to be reviewing Nuplazid for other indications, isn't it sometime in 2019 and what indication will it be review for?
Some would save average down here. Others would say, never throw good money after bad...
It's a shame I read an article from a female reporter a year ago, that ACAD could soon be a buy out target, so it's too bad I took that to heart and bought in (going against my gut.)
It's also a shame that CNN wrote and inaccurate hit piece about Nuplazid, which caused the share price to drop 50%.
Biotech/pharmaceutical investments have always been a dangerous risk, but I think even much more now, in part due to the increase in technology, which obsoletes some drugs, which could happen here with Nuplazid.
Going back to fake new CNN, the problem is that some investors and some doctors believed the article and won't invest, or won't prescribe as much. The main problem with fake news, is once it's a headline, people ten to believe it based on emotion and don't dig any deeper. Also, if CNN posted a retraction, it would be on page 100 and few would ever read it.
Re: nsomniyak; I understand what you are saying, the article was like comparing apples to oranges. However, they way the article detail explaining the valuations of stocks was interesting to me, therefore I think the information was worth posting.
Re Jtalyor; Yes, all joking aside, losses or paper losses have taught me to behave more like a proper investor, but I still do complain sometimes.
Re: biotech2; Ok man, that sounds like a big win, congratulations!
Re: JB, No I believe you were correct and that there was some real reason it was noted at .16 after hours and not noted at .16 the next morning. I'm going to call this a blip, I've seen it with other stocks. I've also seen it where after market close it shoots straight up and goes back down. I've seen it where the is all the sudden a huge spread between bid and ask price, then in the morning it's back. I won't consider this as a final death surge pulse on the ole hospital scope.
Tomorrow, we go up for no reason. I'll have been invested for 2 years in August. It's looking like a win win. No longer will I be down 40%.